Factor Xa Inhibitors

"Factor Xa Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Endogenous factors and drugs that inhibit or block the activity of FACTOR XA.

Descriptor ID	D065427
MeSH Number(s)	D27.505.519.389.745.800.449.500 D27.505.954.502.119.500.500
Concept/Terms	Factor Xa Inhibitors Factor Xa Inhibitors Inhibitors, Factor Xa Direct Factor Xa Inhibitors

Below are MeSH descriptors whose meaning is more general than "Factor Xa Inhibitors".

Chemicals and Drugs [D]
Chemical Actions and Uses [D27]
Pharmacologic Actions [D27.505]
Molecular Mechanisms of Pharmacological Action [D27.505.519]
Enzyme Inhibitors [D27.505.519.389]
Protease Inhibitors [D27.505.519.389.745]
Serine Proteinase Inhibitors [D27.505.519.389.745.800]
Antithrombins [D27.505.519.389.745.800.449]
Factor Xa Inhibitors [D27.505.519.389.745.800.449.500]
Therapeutic Uses [D27.505.954]
Hematologic Agents [D27.505.954.502]
Anticoagulants [D27.505.954.502.119]
Antithrombins [D27.505.954.502.119.500]
Factor Xa Inhibitors [D27.505.954.502.119.500.500]

Below are MeSH descriptors whose meaning is related to "Factor Xa Inhibitors".

Below are MeSH descriptors whose meaning is more specific than "Factor Xa Inhibitors".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Factor Xa Inhibitors" by people in this website by year, and whether "Factor Xa Inhibitors" was a major or minor topic of these publications.

Bar chart showing 54 publications over 18 distinct years, with a maximum of 6 publications in 2013 and 2014 and 2016 and 2020

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2003	0	1	1
2005	0	1	1
2008	0	1	1
2009	0	1	1
2011	0	1	1
2012	0	1	1
2013	2	4	6
2014	1	5	6
2015	3	2	5
2016	3	3	6
2017	0	2	2
2018	2	0	2
2019	3	2	5
2020	5	1	6
2021	2	2	4
2023	0	1	1
2024	3	1	4
2025	1	0	1

Below are the most recent publications written about "Factor Xa Inhibitors" by people in Profiles.

Ibrahim A, Shalabi L, Zreigh S, Ramadan S, Mourad S, Eljadid G, Beshr M, Abdelaziz A, Elhadi M, Sabouret P, Mamas M. Comparative Efficacy and Safety of Low-Dose Direct Oral Anticoagulants Versus Dual Antiplatelet Therapy Following Left Atrial Appendage Occlusion in Patients With Nonvalvular Atrial Fibrillation: A Systematic Review and Meta-Analysis. Catheter Cardiovasc Interv. 2025 05; 105(6):1311-1319.

View in: PubMed
Halawi H, Sabawi MM, Rizk E, Mahmoud AA, Petkova JH, Hui SR, Srour N, Donahue KR. Bleeding outcomes in critically ill patients on heparin with discordant aPTT and anti-Xa activity. J Thromb Thrombolysis. 2025 Feb; 58(2):210-219.

View in: PubMed
Jain SS, Mahaffey KW, Pieper KS, Shimizu W, Potpara T, Ruff CT, Kamel H, Lewis BS, Cornel JH, Kowey PR, Horrow J, Strony J, Plotnikov AN, Li D, Weng S, Donahue J, Gibson CM, Steg PG, Mehran R, Weitz JI, Johnston SC, Hankey GJ, Harrington RA, Lam CSP. Milvexian vs apixaban for stroke prevention in atrial fibrillation: The LIBREXIA atrial fibrillation trial rationale and design. Am Heart J. 2024 11; 277:145-158.

View in: PubMed
Zheng R, Lam E, Altshuler P, Crutcher M, Lavu H, Yeo CJ, Stickle D, Leiby B, Kraft WK. Pharmacokinetics of apixaban in patients undergoing pancreaticoduodenectomy (PAP-UP). Int J Clin Pharmacol Ther. 2024 Jul; 62(7):319-325.

View in: PubMed
Henshaw DS, Schwenk ES, Gupta RK. Evaluating residual anti-Xa levels following discontinuation of treatment-dose enoxaparin in patients presenting for elective surgery: an infographic. Reg Anesth Pain Med. 2024 02 05; 49(2):102-103.

View in: PubMed
Ezekowitz MD, Kamareddine M. Filling an Important Knowledge Gap: The DOAC Score. Circulation. 2023 09 19; 148(12):947-949.

View in: PubMed
Merli GJ, Kraft WK, Eraso LH, Galanis T, Thomson LJ, Ouma GO, Viscusi E, Gong JZ, Lam E. Apixaban Discontinuation for Invasive Or major Surgical procedures (ADIOS): A prospective cohort study. Vasc Med. 2022 06; 27(3):269-276.

View in: PubMed
Albers GW, Bernstein R, Brachmann J, Camm AJ, Fromm P, Goto S, Granger CB, Hohnloser SH, Hylek E, Krieger D, Passman R, Pines JM, Kowey P. Reexamination of the Embolic Stroke of Undetermined Source Concept. Stroke. 2021 08; 52(8):2715-2722.

View in: PubMed
Chaudhry UA, Ezekowitz MD, Gracely EJ, George WT, Wolfe CM, Harper G, Harper GR. Comparison of Low-Dose Direct Acting Anticoagulant and Warfarin in patients Aged =80 years With Atrial Fibrillation. Am J Cardiol. 2021 08 01; 152:69-77.

View in: PubMed
Turakhia M, Sundaram V, Smith SN, Ding V, Michael Ho P, Kowey PR, Piccini JP, Foody J, Birmingham MC, Ianus J, Rajmane A, Mahaffey KW. Efficacy of a centralized, blended electronic, and human intervention to improve direct oral anticoagulant adherence: Smartphones to improve rivaroxaban ADHEREnce in atrial fibrillation (SmartADHERE) a randomized clinical trial. Am Heart J. 2021 07; 237:68-78.

View in: PubMed

People

Explore

Similar Concepts

Top Journals

The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement